# Amantadine for COVID-19

> **NCT04894617** · PHASE3 · UNKNOWN · sponsor: **Copenhagen University Hospital, Hvidovre** · enrollment: 226 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Amantadine
- **DRUG:** Lactose monohydrate

## Key facts

- **NCT ID:** NCT04894617
- **Lead sponsor:** Copenhagen University Hospital, Hvidovre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2022-01
- **Final completion:** 2022-04
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894617, "Amantadine for COVID-19". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04894617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*